LONDON, UK / ACCESS Newswire / June 26, 2026 / Guardian Metal Resources plc (NYSE.A:GMTL)(LON:GMET)(OTCQB:GMTLF), a strategic ...
A phase 3 trial evaluates the efficacy of mezigdomide plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in ...
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today positive results from the Phase III Krascendo 1 study evaluating divarasib, an investigational next-generation KRAS ...
Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Divarasib showed clinically meaningful improvements in ...
After a four-month investigation, Nature Medicine has decided to pull a viral study that linked early-day PD-1/chemo ...
SEQUOIA subgroup shows zanubrutinib sustains 64% PFS at 6 years in CLL patients ≥80, with low early discontinuations and ...
MedPage Today on MSN
Recent Developments in Prostate Cancer
Practice-changing perioperative therapy, chemo-free combo for CSPC, reducing cognitive eff ...
Post hoc analysis of the MajesTEC-3 trial shows the efficacy of the teclistamab plus daratumumab combination in hard-to-treat patients with high cytogenetic and functional risk.
The Swedish government has granted Leading Edge Materials (TSXV: LEM) a 25-year mining lease for what the company calls one ...
MedPage Today on MSN
Triplet Could Become a New Standard in Tough-to-Treat CLL
Adding a non-covalent BTK inhibitor improved progression-free survival ...
Today, Alliance Foundation Trials, LLC (AFT) was informed that the U.S. Food and Drug Administration has approved palbociclib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results